title: Genetic variation of genes for xenobiotic-metabolizing enzymes and risk of bronchial asthma: the importance of gene-gene and gene-environment interactions for disease susceptibility.
abstract: The aim of our pilot study was to evaluate the contribution of genes for xenobiotic-metabolizing enzymes (XMEs) for the development of bronchial asthma. We have genotyped 25 polymorphic variants of 18 key XME genes in 429 Russians, including 215 asthmatics and 214 healthy controls by a polymerase chain reaction, followed by restriction fragment length polymorphism analyses. We found for the first time significant associations of CYP1B1 V432L (P=0.045), PON1 Q192R (P=0.039) and UGT1A6 T181A (P=0.025) gene polymorphisms with asthma susceptibility. Significant P-values were evaluated through Monte-Carlo simulations. The multifactor-dimensionality reduction method has obtained the best three-locus model for gene-gene interactions between three loci, EPHX1 Y113H, CYP1B1 V432L and CYP2D6 G1934A, in asthma at a maximum cross-validation consistency of 100% (P=0.05) and a minimum prediction error of 37.8%. We revealed statistically significant gene-environment interactions (XME genotypes-smoking interactions) responsible for asthma susceptibility for seven XME genes. A specific pattern of gametic correlations between alleles of XME genes was found in asthmatics in comparison with healthy individuals. The study results point to the potential relevance of toxicogenomic mechanisms of bronchial asthma in the modern world, and may thereby provide a novel direction in the genetic research of the respiratory disease in the future.
authors: Department of Biology, Medical Genetics and Ecology, Kursk State Medical University, Kursk, Russia. polonikov@rambler.ru
authors: Alexey V
authors: AV
authors: Polonikov
authors: Vladimir P
authors: VP
authors: Ivanov
authors: Maria A
authors: MA
authors: Solodilova
mesh_terms: D000328:Adult; D001189:Aryl Hydrocarbon Hydroxylases; D043303:Aryldialkylphosphatase / Q000235:genetics*; D001249:Asthma / Q000235:genetics*; D016022:Case-Control Studies; D065633:Cytochrome P-450 CYP1B1; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004851:Epoxide Hydrolases / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation / Q000235:genetics*; D005838:Genotype; D014453:Glucuronosyltransferase / Q000235:genetics*; D006801:Humans; D008297:Male; D010865:Pilot Projects; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D012307:Risk Factors; D015262:Xenobiotics / Q000378:metabolism
chemical_list: D015262:Xenobiotics; D003577:Cytochrome P-450 Enzyme System; D001189:Aryl Hydrocarbon Hydroxylases; C585496:CYP1B1 protein, human; D065633:Cytochrome P-450 CYP1B1; D019389:Cytochrome P-450 CYP2D6; C110655:UDP-glucuronosyltransferase, UGT1A6; D014453:Glucuronosyltransferase; D043303:Aryldialkylphosphatase; C468406:PON1 protein, human; D004851:Epoxide Hydrolases; C522330:EPHX1 protein, human